A Bay Area-based company that sells an innovative blood test just released the results of a major clinical trial. 

A Silicon Valley-based company’s innovative blood test, designed to identify cancer early, hit the market five years ago and even cameoed in a recent Super Bowl ad.  

But new results from a large clinical trial revealed that the blood test did not significantly reduce advanced cancer diagnoses, the maker Grail announced on Thursday. 

Article continues below this ad

Although Grail highlighted silver linings in the trial findings, the company’s stock cratered by 50% on Friday. 

“As the stock market reacted, I think those results are not sufficiently impressive to be transformative,” Ash Alizadeh, a researcher who leads the Stanford Cancer Institute’s cancer genomics program, told SFGATE. “It kind of breaks my heart to see the study be negative.”

Grail has sold its blood test, called Galleri, in the U.S. for just under........

© SFGate